8 results
Primary:To determine the efficacy of AG10 in the treatment of subjects with symptomatic transthyretin amyloid polyneuropathy (ATTR-PN) by evaluating the difference between the AG10 and placebo groups in Modified Neuropathy Impairment Score + 7 (mNIS…
To confirm our previous findings that both TUS and auditory cuing decreases MEP amplitude in an independent sample using a more efficient design. Reducing the number of principal conditions will benefit data quality and allow for better estimation…
Our primary objective is to elucidate the neurophysiologic effects of short-term TUS on deep brain circuits in humans. We will map the effects of TUS targeting the amygdala vs. two subregions of the thalamus (mediodorsal & pulvinar nucleus)…
Key PrimaryPart A• To determine the efficacy of acoramidis (AG10) in the treatment of subjects with symptomatic transthyretin amyloid cardiomyopathy (ATTR-CM) by evaluating the difference between the acoramidis and placebo groups in the change from…
The primary objective is to assess the causal role of the human amygdala in fear learning, by indexing the impact of TUS targeting the amygdala on physiological markers of fear. The secondary objectives are to (1) discern the neuromodulatory effects…
Our primary objective is to translate an in non-human primate established online TUS protocol to humans. To this end, we will investigate how this protocol influences choice behaviour in humans, by stimulating the left and right FEF in a saccade…
Primary• To assess safety and tolerability of acoramidis in participants with symptomatic transthyretin amyloid cardiomyopathy (ATTR-CM)Secondary• To evaluate the effect of acoramidis on all-cause mortality (ACM) and cardiovascular (CV) mortality•…
Primary Objectives:- To estimate complete response rate, per pathology review committee (PRC), and its duration in CIS participantsSecondary Objectives:- To evaluate progression free survival, per pathologie review committee (PRC), for all…